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HERBERT J. KRAMER, KILIAN GLANZER, and RAINER DUSING
Medizinische Universitäts-Poliklinik, Bonn, West Germany
Accumulating evidence suggests that the renal
prostaglandin (PG) system participates in the regu-
lation of renal water excretion. In the renal medulla,
high PG synthetase activity is present in the intersti-
tial cells [1] and the collecting duct epithelium [2, 3].
Also, in vitro studies in the toad urinary bladder [4]
and the isolated collecting duct [5] have demon-
strated that PGE suppresses vasopressin-induced
changes in water permeability in these tissues,
possibly by inhibiting vasopressin-activated adenyl-
cyclase. In addition, administration of vasopressin
to acutely hypophysectomized dogs [6] or healthy
volunteers [7] resulted in a significantly enhanced
urinary concentrating response when PG synthesis
was inhibited with nonsteroidal antiinflammatory
agents. Furthermore, in vitro studies in rabbit reno-
medullary interstitial cell cultures [8] and the toad
urinary bladder [9] have shown that arginine vaso-
pressin stimulates PGE2 biosynthesis in these tis-
sues. Therefore, a short loop feedback system has
been proposed in which arginine vasopressin itself
stimulates its antagonist PGE2 in collecting duct
epithelial cells [9, 101.
The mechanism of the antagonistic action of PGE
on vasopressin-induced changes in water excretion
is still controversial. In addition to the above men-
tioned in vitro studies, the concept of an inhibitory
action of PGE on vasopressin-activated adenylcy-
clase has also been supported by measurements of
renal medullary tissue cyclic adenosine monophos-
phate (cyclic AMP) concentrations in response to
exogenous vasopressin in the rat, which significant-
ly increased following inhibition of PG synthesis
with indomethacin [11].
The concentrating ability of the kidney is mainly
dependent on: (1) glomerular filtration rate (GFR)
and proximal tubular function to determine fluid
and solute delivered to distal segments of the neph-
ron, (2) sodium and chloride absorption in the thick
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ascending limb of Henle's loop, (3) the availability
of urea to determine passive sodium and chloride
absorption in the thin ascending limb of Henle's
loop, (4) medullary blood flow as a modulator of
interstitial osmotic driving forces, and (5) adequate
secretion of vasopressin and tubular responsiveness
to this hormone to determine finally the degree of
water permeability of the collecting duct epitheli-
um.
Recent experimental evidence suggests that the
renal PG system may affect at least some of these
variables. The present paper will therefore review
the possible interaction of renal PG's with the
above mentioned determinants of renal concentrat-
ing ability. Furthermore, the potential mechanisms
by which this local hormonal system may affect
urine concentrating ability will be discussed on the
basis of studies performed in our laboratory.
Urinary PGE2 excretion and urine flow
Recent studies have suggested that urinary PGE2
excretion may largely depend on urinary flow rate.
Thus, Kaye et al [12] observed a close correlation
between urine flow and urinary PGE2 excretion in
normal volunteers during water loading when the
urinary PGE2 concentration was measured by ra-
dioimmunoassay. In addition, Kirschenbaum and
Serros [13], using a membrane receptor assay,
observed a linear relationship between urinary PGE
excretion and urine flow rate in conscious dogs
during antidiuresis, maximal water loading without
and with simultaneous vasopressin administration,
and during mannitol infusion. They concluded from
these results that urinary PGE excretion is deter-
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mined to a large extent by urinary flow rate. Lif-
schitz et a! [141 also suggested that water diuresis
stimulates renal PGE excretion in the dog.
In contrast, DUsing, Overlack, and Kramer [151
demonstrated that apparent increases in urinary
excretion of PGE2 and PGF2c. during water loading
in healthy volunteers with a more than fourfold
increase in urine volume may be entirely due to
methodologic problems inherent in PG measure-
ments by radioimmunoassay. These may be primar-
ily related to a small though relevant water blank
measured in extracts of 1 to 5 ml of urine. This
blank then becomes critical when PG concentra-
tions are measured in small urine samples and used
for calculation of urinary PG excretion in situations
of a markedly increased urine volume.
Urinary PGE2 excretion during oral water load-
ing in healthy volunteers. Six healthy volunteers
were studied on a control day with ad lib fluid
intake and again on the next day during oral water
loading by drinking I liter of water every 4 hours.
The mean urinary flow rate increased from 1203
242 mi/day during control periods to 5072 320
mi/day during oral water loading. With convention-
al measurements of urinary immunoreactive PGE2
concentration, urinary PGE2 excretion of 163 23
ng/day on the control day rose to 669 89 ng/day
during water loading and revealed a close linear
correlation between urine volume and urinary PGE2
excretion (r = 0.71; P < 0.01). But, when polyuric
urine samples were concentrated to volumes equal
to control periods (without affecting PG recovery),
the observed rise in PGE2 excretion following water
loading was of borderline significance only, with a
mean value of 356 61 ng/day (P = 0.05) (Fig. 1).
Similarly, urinary PGF2a excretion rose from 319
17 to 995 88 ng/day according to the results
obtained by the conventional assay method, but this
difference was completely eliminated when urine
volume was adjusted to the control volume prior to
the assay. This then resulted in a PGF2a excretion
of 355 77 ng/day [15]. Although no PG measure-
ments by gas chromatography mass spectrometry
are available to resolve the controversial results,
our data strongly suggest that radioimmunoassay
measurements of PG in large urine volumes may be
hampered by inherent blank problems and should
be interpreted cautiously.
Urinary PGE2 excretion in patients with central
diabetes insipidus. In accordance with studies in
healthy volunteers and in animals suggesting that
urinary PG excretion may largely depend on urine
flow, Fichman, Zia, and Zipser [16] observed in-
creased urinary immunoreactive PGE2 excretion in
patients with central and nephrogenic diabetes in-
sipidus. In contrast, Dusing, Herrmann, and Kra-
mer [171 observed a mean urinary PGE2 excretion
of 305 30 ng/day in three family members with
hereditary and in one patient with idiopathic central
diabetes insipidus when native urine was used (Ta-
ble 1). This value was within the normal range with
respect to their salt-balance. But, when urine vol-
umes of these polyuric patients were concentrated
to volumes similar to those of control subjects,
urinary PGE2 excretion measured 86 23 ng/day in
patients with central diabetes insipidus. This obser-
vation is in accordance with the low urinary PGE2
excretion demonstrated in rats with hereditary cen-
tral diabetes insipidus [18, 191.
Renal PG synthesis may be stimulated by endoge-
nous angiotensin II (All). Therefore, the question
arises, whether the observed changes in urinary
PGE2 excretion may have resulted from altered
activity of the renin-angiotensin system. During
oral water loading, the observed rise in PGE2
excretion of borderline statistical significance was
in fact accompanied by a slight but insignificant rise
in upright plasma renin activity (PRA). Patients
with central diabetes insipidus previously have
been shown to have a stimulated renin-angiotensin
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Fig. 1. Changes in urinary PGE2 excretion with polydipsic water
loading in six healthy volunteers. Radioimmunologic PGE2 mea-
surements were performed in native polyuric urine samples
(open area) and in polyuric urine samples (shaded area) volume-
adjusted to control urine volumes (see text). Areas represent the
means SEM of control and polyuric collection periods.
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system [20]. We therefore determined plasma renin
these patients on several occasions before treat-
ment was initiated 2 years ago and again at the time
of the present study after they had not taken
medication for at least 1 week. They all revealed
low supine and upright plasma renin activities,
possibly due to the increase in serum sodium con-
centration (Table 1).
Thus, the low activity of the renin-angiotensin
system may well have contributed to the low uri-
nary PGE2 excretion observed in our patients with
central diabetes insipidus.
Dependence of renal prostaglandin synthesis on
arginine vasopressin (AVP) and AVP analogues in vivo
Effects of exogenous lysine vasopressin and des-
amino-arginine vasopressin on urinary PGE2 excre-
tion. In salt-repleted healthy subjects with a low
supine plasma renin activity averaging 0.20 ng/ml
per 3 hours, administration of a single dose of 100
mU of lysine vasopressin significantly enhanced
urinary PGE2 excretion from 0.26 0.09 to 0.45
0.12 ng/min (P < 0.05) [7]. This was also observed
during a second study when subjects were on a
normal salt intake (Fig. 2). Similarly, in our patients
with central diabetes insipidus and low supine plas-
ma renin activity of 0.32 ng/ml per 3 hours, desa-
mino-arginine vasopressin administered twice daily
intranasally at a dose of 7.5 tg markedly increased
daily urinary PGE2 excretion from 86 23 (see
above) to 925 237 nglday (P < 0.01). Desamino-
arginine vasopressin further suppressed supine
plasma renin activity to an average of 0.20 ng/ml per
3 hours (Table 1). This vasopressin analogue there-
fore must have exerted a direct effect on renal PG
synthesis, although previous in vitro studies failed
to demonstrate such activation by desamino-argi-
nine vasopressin [21], in contrast to the effect of
arginine vasopressin on PG synthesis [9, 21]. Thus,
under conditions of a suppressed renin-angiotensin
system, both lysine vasopressin and desamino-argi-
nine vasopressin significantly enhanced urinary
PGE2 excretion, probably reflecting increased
PGE2 synthesis in collecting duct epithelial cells.
Relative potency of arginine vasopressin to stim-
ulate renal prostaglandin synthesis. Although a
marked stimulation of renal PG biosynthesis by
arginine vasopressin, lysine vasopressin, and desa-
mino-arginine vasopressin PG synthesis was thus
demonstrated, the renin-angiotensin system may be
a more important determinant of renal PG synthesis
in vivo. To examine this possibility, we performed
the following studies. With i.v. infusion of isotonic
saline, the urinary PGE2 excretion in healthy sub-
jects was suppressed from 0.45 0.06 to 0.15
0.05 nglmin (P < 0.01) [22]. The i.v. infusion of
hypertonic (2.5%) saline to healthy volunteers also
resulted in a significant decrease in urinary PGE2
excretion from 0.57 0.14 to 0.24 0.07 ng/min (P
< 0.01) [22]. Because hypertonic saline infusion
was associated with an increase in urinary excretion
of arginine vasopressin from 163 26 to 317 41
fmoles/min (P < 0.0001) and suppressed plasma
renin activity from a mean of 1.22 to 0.20 ng/ml per
Table 1. Effects of desamino-arginine vasopressin (dDAVP) (15 tg/day) and dDAVP plus indomethacin (INDO) (150 mg/day) in five
patients with central diabetes insipidusa
dDAVP
Control dDAVP + INDO
Urine volume, mi/day 10838 107 1205 204" 945 131
Uom, mOsm/kg 1120 75 8 460 72" 685 48"
CH2O, mi/mm
Ccr, mI/mm
5.62 0.68
125.4 11.4
—0.41 017b
104.4 4.1
—0.93 0.14"
110.0 11.3
PGE2, ng/day 305 30 925 237 318 88
PGF2a, ng/day 559 213 454 110 224 61
UCAMP, pmo1es/day 2.55 0.64 4.91 0.751 5.02 0.59
P0, m0sm/kg H20 286 2 278 2" 276 2
SNa, mEq/iiter 148.6 1.2 143.4 l.7' 141.0 1.8
SK, mEq/liter 4.1 0.1 4.1 0.1 4.5 0.1
PRA sup., ng/ml3 hr 0.32 0.16 0.20 0.04 <0.16
PRA up., ng/mi3 hr 0.94 0.24 0.25 0.09 0.20 0.04
PAIdO sup., pg/mi 71.2 6.2 80.4 4.7 88.0 15.1
PAId0 up., pg/mi 107.2 38.2 89.5 37.0 126.0 46.4
a Prostaglandin excretion data are calculated from measurements in native not volume-adjusted
patients with diabetes insipidus. (Values taken from Ref. 17).
"P <0.001.P < 0.01.
"'P < 0.05.
(see text) urine samples of four
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Fig. 2. Urinary osmolality free water clearance (CH2O),
and urinary cyclic AMP (UAMP), and PGE2 excretion (UPGEV)
in five healthy subjects during control periods and during
maximal anridiuresis following i.v. injection of lysine-vasopres-
sin (LVP) in the absence and presence of PG-synthesis inhibition
with indomethacin (INDO).
3 hours 1123], it seems therefore that renal PG
biosynthesis paralleled the suppression of plasma
renin activity rather than the increase in plasma
vasopres sin concentrations. This observation
agrees with previous in vitro studies in which
arginine vasopressin concentrations approximately
500-fold higher than those of All were necessary to
obtain maximal stimulation of PGE2 synthesis by
rabbit renomedullary interstitial cells in culture 118].
Similar to these in vitro results, our results clearly
show that endogenous vasopressin is a relatively
weak stimulator of renal PG biosynthesis as com-
pared with All in vivo.
Renal water excretion in the absence and presence of
prostaglandin synthesis inhibition
Studies in healthy subjects. In healthy subjects,
the infusion of hypertonic (2.5%) saline increased
urinary excretion of sodium and osmolar clearance
in the presence of a slight fall in urine volume. None
of these effects of saline administration were signifi-
cantly affected by a concomitant inhibition of PG
synthesis. Urinary osmolality rose from 332 107
Control dDAVP dDAVP
(15 g Ln.) +lndo
Fig. 3. Effects of intranasally administered desamino-arginine
vasopressin (dDAVP) on urinary osmolality (Uosm), free water
clearance (CH2O), and on urinary cyclic AMP (UAMP), and
PGE2 excretion (UPGE2V) in patients with central diabetes
insipidus in the absence and presence of PG synthesis inhibition
with indomethacin (INDO).
to 641 81 mOsm/kg H20 (P < 0.01) during
hypertonic saline administration alone [23]. In con-
trast to the observations with i.v. infusion of isoton-
ic saline in which concomitant inhibition of PG
synthesis had no effect on free water absorption
[221, simultaneous indomethacin treatment during
hypertonic saline infusion further potentiated the
rise in urinary osmolality to 816 84 mOsm/kg
H20. This difference in urinary osmolality between
hypertonic saline infusion without and with con-
comitant indomethacin treatment was highly signifi-
cant (P < 0.01). In parallel, free water absorption,
which increased during hypertonic saline infusion
from —3.50 2.23 to 2.21 0.62 mL'min (P <
0.05), also showed a slight further increase to 3.02
0.27 mi/mm when hypertonic saline was adminis-
tered during inhibition of PG synthesis [23].
Similarly, in healthy subjects, urinary osmolality
following administration of a single dose of 100 mU
lysine vasopressin averaged 839 47 mOsm/kg
H20 in the absence of indomethacin and 996 62
mOsm/kg H20 in the presence of indomethacin (P <
0.01) [7] (Fig. 2).
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Studies in patients with central diabetes insipi-
dus. In patients with central diabetes insipidus,
urine flow was normalized by the second day of
desamino-arginine vasopressin treatment and uri-
nary osmolality increased from 75 8 to 460 72
mOsm!kg H20 (P < 0.01). This was paralleled by a
decrease in free water clearance from 5.62 to —0.41
ml/min (P < 0.001) in the absence of changes in
GFR. These renal functional changes were associat-
ed with a significant decrease in plasma osmolality
from 286 2 to 278 2 mOsm/kg H20 (P < 0.05)
and serum sodium concentration from 149 1 to
143 2 mEq/liter (P < 0.05) (Table 1). Concomi-
tant indomethacin and desamino-arginine vasopres-
sin administration slightly but insignificantly de-
creased urine volume from 1205 204 to 945 131
ml/day as compared with desamino-arginine vaso-
pressin treatment alone. Urinary osmolality further
increased from 460 72 to 685 48 mOsm/kg H20(P < 0.01) and free water clearance decreased from
—0.41 to —0.93 mi/mm (P < 0.05) (Fig. 3) without
changes in GFR or urinary excretion of sodium and
potassium [17] (Table 1).
Interactions of prostaglandins with factors controlling
renal water excretion
Effects of prostaglandins on GFR, and proximal
and distal tubular function. Both GFR and proximal
tubular function participate in the renal concentrat-
ing and diluting mechanism by determining the
amount of solute and water reaching the distal
"diluting segments" of the nephron. The observa-
tion that most patients with advanced renal failure
are incapable of concentrating their urine may sug-
gest that the amount of glomerular filtrate reaching
the distal tubule is an essential prerequisite for renal
concentrating ability (see Ref. 24).
Numerous studies with either infusion of exoge-
nous PG's or inhibition of endogenous PG biosyn-
thesis have investigated the effect of such proce-
dures on GFR and proximal tubular function. Al-
though most studies in animals or in healthy human
subjects were unable to detect changes in GFR
during PG synthesis inhibition [7, 22, 25—30], it has
been reported that PG inhibition may reduce GFR
in patients with nephrotic syndrome [29], and B art-
ter's syndrome [31]. A reduction of GFR in healthy
man following indomethacin treatment was ob-
served only during marked sodium restriction [32].
In studies performed in this laboratory, we were
unable to detect changes in GFR in rats under
control conditions or during isotonic saline infusion
[25, 271, and in healthy volunteers during infusion of
isotonic [221 and hypertonic (2.5%) [7, 231 or hypo-
tonic (0.45%) saline [30] when PG synthesis was
inhibited with indomethacin. During hypertonic sa-
line infusion, no changes in GFR occurred, al-
though a marked rise in urinary osmolality and a
further increase in free water adsorption were ob-
served [7, 231.
It seems reasonable to conclude, therefore, that
inhibition of PG biosynthesis may only decrease
GFR in certain renal and electrolyte disorders or
during excessive salt restriction, probably as a
result of impaired renal blood flow.
The question of whether the proximal tubule
represents a site of action of the PG system within
the kidney has been investigated extensively. Infu-
sion of PGE into the renal artery of the dog had no
effect on proximal tubular function despite a
marked increase in urinary sodium excretion [333.
Also, micropuncture experiments have largely ex-
cluded the proximal tubule from participating in the
renal response to inhibition of PG biosynthesis [28,
34, 35]. In healthy human volunteers, DUsing et al
[30] were unable to detect changes in proximal
tubular function as determined by clearance meth-
ods during inhibition of PG synthesis despite a
marked reduction in urinary excretion of sodium,
chloride, and potassium. It seems unlikely, there-
fore, that effects of the renal PG system on the
regulation of renal water excretion may be mediated
through alterations in the delivery of solute and
water to the diluting segment.
Further evidence pointing to the distal tubule as
one site of action of renal PG's was presented by
Ganguli et al [36]. In their study, rat papillary
chloride concentration was significantly increased
during inhibition of PG synthesis, and this increase
in papillary solute concentration was independent
of changes in papillary blood flow. This study
therefore indicated that PG may inhibit electrolyte
transport in the ascending limb of Henle's loop or
the collecting duct.
Furthermore, in vitro studies demonstrated that
PGE2 inhibits sodium chloride transport in isolated
segments of rabbit nephrons such as the isolated
medullary thick ascending limb of Henle's loop [37]
and the cortical and outer medullary collecting
tubule [38, 391.
We have therefore performed studies to investi-
gate the effect of PG synthesis inhibition on distal
tubular function using clearance methods in normal
volunteers. In these studies, distal fractional chlo-
ride absorption was significantly increased by indo-
methacin in the absence of changes in GFR or
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proximal tubular function. It appears from these
results, therefore, that sodium retention following
administration of nonsteroidal antiinfiammatory
drugs is due to a PG-mediated effect on electrolyte
absorption in the diluting segments of the nephron,
presumably the ascending limb of Henle's loop [301.
Effects of prostaglandins on renal blood flow and
intrarenal blood flow distribution. Conflicting re-
sults have been reported about the effects of PG's
on renal hemodynamics. Although systemic or in-
trarenal infusion of PG's may not mimic the physio-
logic role of this locally acting endogenous hormone
system, it has previously been observed that PG's
do affect renal hemodynamics with a predominant
rise in medullary blood flow; this effect could be an
important determinant of the osmotic interstitial
gradient in the renal medulla. Although Zins [401
was unable to demonstrate that inhibition of PG
synthesis alters total renal blood flow in the con-
scious dog, we have recently shown in healthy
saline-loaded subjects that administration of indo-
methacin significantly reduced PAH clearance from
621 32 to 447 88 ml/min/l.73 m2 (P < 0.01)
[221. But, it may be inferred that indomethacin
alters PAH-secretion at the level of the organic
anion pump. Nevertheless, we previously observed
a decrease in '251-hippuran clearance of similar
magnitude in the saline-loaded rat, but the same
dose of indomethacin had no effect on '251-hippuran
clearance in nonexpanded control rats [26, 271.
However, inhibition of PG synthesis in control
animals was associated with a relative and absolute
decrease in inner cortical and medullary blood flow
[271. This is also supported by the changes in deep
cortical flow that we observed following the sup-
pression of PG synthesis by the administration of
aprotinin [411, a peptide that inhibits kallikrein
formation and that presumably is not secreted by
the organic anion pump. Thus, renal PG's may
affect total renal or medullary blood flow as one
determinant of the medullary interstitial osmotic
gradient.
Effect of indomethacin on circulating arginine
vasopressin. A preliminary study suggested that
urinary arginine vasopressin excretion decreased
during indomethacin treatment in man [42]. We
have therefore investigated the interrelation of argi-
nine vasopressin and renal PG's in healthy volun-
teers. In this study, urinary arginine vasopressin
excretion was decreased slightly by indomethacin
under control conditions from 163 25 to 127 37
fmoles/min, but a marked and statistically signifi-
cant suppression of arginine vasopressin excretion
by indomethacin from 317 40 to 240 37
fmoles/min (P < 0.02) was observed during stimula-
tion of arginine vasopres sin excretion by infusion of
hypertonic saline. The mechanism of this effect of
indomethacin remains speculative. Prostaglandin
synthesis inhibition enhanced renal water absorp-
tion during hypertonic saline infusion, resulting in a
significantly smaller rise in plasma osmolality from
282 2 to 294 2 mOsm/kg H20 as compared with
the rise from 283 2 to 301 2 mOsm/kg H20
observed during saline infusion alone [231. This
blunted response of plasma osmolality to hyperton-
ic saline infusion would consequently result in a
smaller stimulation of arginine vasopressin secre-
tion. In addition to such an adaptive suppression of
arginine vasopressin secretion during indomethacin
treatment, a direct or PG-mediated central effect of
indomethacin on arginine vasopressin secretion
[43—451 cannot be excluded. This possibility is
suggested by the slight, though not significant,
suppression of urinary arginine vasopressin excre-
tion during control periods when indomethacin had
essentially no effect on plasma osmolality. In an in
vitro assay system of guinea pig hypothalamo-
neurohypophyseal organ culture, All and PGE2
were both shown to release arginine vasopressin in
a dose-dependent manner, but All revealed a more
than twofold stronger effect than PGE. Although
indomethacin had no effect on basal arginine vaso-
pressin release, it completely abolished the All-
stimulated arginine vasopressin release in this in
vitro study [46]. In summary, because suppression
of arginine vasopressin excretion during indometh-
acm treatment became statistically significant only
during osmoreceptor-mediated stimulation of argi-
nine vasopressin secretion, this indomethacin-in-
duced suppression of arginine-vasopressin secre-
tion may have resulted indirectly from increased
water retention. In addition, indomethacin may
suppress vasopressin secretion by a direct central
action of the drug or through inhibition of PG
synthesis.
Prostaglandins and urinary adenosine mono-
phosphate. Because the action of vasopressin on
collecting duct water permeability is probably medi-
ated by the formation of cyclic adenosine mono-
phosphate (cyclic AMP), we have measured urinary
excretion of cyclic AMP under different experimen-
tal conditions to further investigate the possible
mechanism of a PG-mediated effect on renal water
excretion. Because the early in vitro experiments in
the toad urinary bladder [41 and the isolated collect-
ing tubule [51 had suggested that the ADH-antago-
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fistic action of PGE might be mediated through an
inhibition of vasopressin-activated adenyl cyclase,
the urinary excretion of cyclic AMP (UCAMPV) was
measured in healthy volunteers under control con-
ditions, during hypertonic (2.5%) saline infusion
and following the administration of exogenous ly-
sine vasopressin (LVP) with and without concomi-
tant indomethacin treatment. In addition, UCAMPY
was determined in patients with central diabetes
insipidus during control (polyuric) conditions and
during treatment with dDAVP and dDAVP plus
indomethacin. Although hypertonic saline as well
as exogenous LVP increased UCAMPV (Fig. 2), no
effect of a concomitant indomethacin treatment
could be observed despite the significant enhance-
ment of urinary solute concentrations (Fig. 2). Also,
in patients with central diabetes insipidus, dDAVP
administration significantly increased UCAMPV from
a mean control value of 2.55 0.64 mole s/day to
4.91 0.75 moles/day (P < 0.05) without an
additional effect of indomethacin treatment (5.02
0.59 p.moles/day) [17] (Table 1; Fig. 3). These
results contrast with the finding in anesthetized rats
in which a single i.v. dose of indomethacin caused a
significantly greater rise in the medullary cyclic
AMP content in response to vasopressin as com-
pared with the same dose of vasopressin alone [11].
They agree, however, with another study in healthy
volunteers, in which the effect of exogenous vaso-
pressin on urinary concentrating ability was also
enhanced by pretreatment with indomethacin in the
absence of changes in urinary cyclic AMP excretion
[471. It seems likely, therefore, that the urinary
excretion of cyclic AMP does not adequately reflect
alterations in the generation of cyclic AMP in
collecting duct epithelium. On the other hand, our
results may point to the possibility that other mech-
anisms contribute to the observed effects of PG-
synthesis inhibition on renal concentrating ability.
Conclusions
To extend previous in vitro studies, we have
shown in healthy human subjects and in patients
with central diabetes insipidus that vasopressin is a
much weaker stimulus of renal PGE synthesis than
is All. Therefore, vasopressin-dependent renal PG
synthesis may become evident only under condi-
tions of low activity of the renin-angiotensin sys-
tem.
Patients with central diabetes insipidus were
found to have a low renal PG synthesis as reflected
by a decreased urinary PGE2 excretion that was
independent of urinary flow rate. The tubular ef-
fects of endogenous arginine vasopressin, as well as
its analogues lysine-vasopressin and desamino-
arginine vasopressin, are markedly enhanced fol-
lowing the inhibition of PG synthesis. This probably
results from: (1) increased sodium and chloride
absorption in the thick ascending limb of Henle's
loop, (2) increased cyclic AMP formation in collect-
ing duct epithelial cells, and (3) decreased medul-
lary blood flow with reduced washout of solute
from the medullary interstitium. In addition, sys-
temic inhibition of PG synthesis was found to also
indirectly or directly suppress osmoreceptor-medi-
ated stimulation of central vasopressin secretion.
Arginine vasopressin, as well as its analogues
lysine vasopressin and desamino-arginine vasopres-
sin, potentially stimulates renal synthesis of PGE.
Medullary interstitial osmolality also may enhance
PGE synthesis [48]. Intrarenal PG may inhibit vaso-
pressin-activated adenylcyclase activity in collect-
ing duct epithelial cells, thus attenuating vasopres-
sin-dependent transtubular water movement. PG
may also inhibit sodium and chloride absorption in
the thick ascending limb of Henle's loop and in-
crease medullary blood flow, thus lowering medul-
lary interstitial osmotic driving forces. Therefore, a
PG-dependent, complex, intrarenal short-loop feed-
back, as well as possible extrarenal mechanisms,
may be involved in the renal regulation of water
balance.
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